Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2018 19:32 ET | Source: Mesoblast Limited

Financial Results and Operational Highlights for the Third Quarter Ended March 31, 2018

MELBOURNE, Australia and NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced strong financial results for the nine months ended March 31, 2018 and...
May 30, 2018 18:41 ET | Source: Mesoblast Limited

Mesoblast Appoints New Chief Financial Officer

MELBOURNE, Australia and NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced the appointment of Josh Muntner as its new Chief Financial Officer,...
May 29, 2018 15:21 ET | Source: Mesoblast Limited

Mesoblast Financial Results Webcast for Quarter Ended March 31, 2018

NEW YORK and MELBOURNE, Australia, May 29, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will report financial results for the quarter ended March 31, 2018 in a webcast...
May 29, 2018 06:00 ET | Source: Mesoblast Limited

Mesoblast Partners With Cartherics to Develop ’off-the-shelf’ Cell-based Immunotherapies for Solid Cancers

NEW YORK and MELBOURNE, Australia, May 29, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has entered into a partnership with Cartherics Pty Ltd to...
May 08, 2018 06:00 ET | Source: Mesoblast Limited

Mesoblast Phase 3 Trial Results for Acute Graft Versus Host Disease Presented at 2018 International Society for Cell and Gene Therapy Annual Meeting

NEW YORK and MELBOURNE, Australia, May 08, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that results of the Phase 3 trial evaluating its product candidate...
May 01, 2018 06:00 ET | Source: Mesoblast Limited

Mesoblast Cell Therapies Featured at Vatican International Healthcare Conference

NEW YORK and MELBOURNE, Australia, May 01, 2018 (GLOBE NEWSWIRE) -- Mesoblast’s proprietary allogeneic cell technology platform was featured at the Unite to Cure Fourth International Vatican...
April 18, 2018 06:00 ET | Source: Mesoblast Limited

Mesoblast Clinical Program Update for MPC-150-IM in Patients With Chronic Heart Failure

NEW YORK and MELBOURNE, Australia, April 18, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today provided an update on the Phase 3 and Phase 2b clinical trials of the Company's...
March 28, 2018 18:25 ET | Source: Mesoblast Limited

Mesoblast Phase 3 Cell Therapy Trial for Chronic Low Back Pain Completes Enrollment

NEW YORK and MELBOURNE, Australia, March 28, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that enrollment has completed in the Phase 3 trial evaluating a single...
March 06, 2018 19:31 ET | Source: Mesoblast Limited

Mesoblast Enters Into US$75 Million Non-Dilutive Credit Facility

MELBOURNE, Australia and NEW YORK, March 06, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that it has entered into a US$75 million non-dilutive, four-year...
February 27, 2018 16:47 ET | Source: Mesoblast Limited

Mesoblast Operational Highlights and Financial Results for the Half-Year Ended December 31, 2017

MELBOURNE, Australia and NEW YORK, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today provided the market with an update on its operational highlights and consolidated...